目的 评价小儿智力糖浆联合哌甲酯治疗注意力缺陷多动障碍的临床疗效及安全性。方法 计算机检索中国学术期刊全文数据库（CNKI）、中国生物医学文献数据库（CBM）、维普中文期刊全文数据库（VIP）、万方数据库、the Cochrane Library、PubMed和Web of Science中英文数据库，收集各数据库建库起至2021年12月26日小儿智力糖浆联合哌甲酯治疗注意力缺陷多动障碍的临床随机对照试验（RCT）。由两位研究人员独立筛选文献、提取资料，使用RevMan 5.4软件分析数据。结果 共纳入9项RCTs、包括861例患儿。Meta分析结果显示：小儿智力糖浆联合哌甲酯组在多动指数评分[MD=-0.32，95% CI（-0.40，-0.23），P<0.000 01]、冲动行为评分[MD=-0.38，95% CI（-0.48，-0.29），P<0.000 01]、学习行为评分[MD=-0.36，95% CI（-0.43，-0.29），P<0.000 01]、不良反应率[RR=0.64，95% CI（0.46，0.89），P=0.009]方面，与对照组比较，差异均有统计学意义。结论 小儿智力糖浆联合哌甲酯治疗注意力缺陷多动障碍的疗效优于单用哌甲酯，且更安全。

Objective To systematically evaluate the clinical efficacy and safety of Xiaoer Zhili Syrup combined with methylphenidate in the treatment of attention-deficit hyperactivity disorder (ADHD). Methods Literature search was conducted across CNKI, CBM, VIP, Wanfang Database, the Cochrane Library, PubMed, and Web of Science, to search for randomized controlled trial (RCT) of Xiaoer Zhili Syrup combined with methylphenidate in the treatment of ADHD. The retrieval time is from the establishment of the database to December 26, 2021. There are two researchers that independently screened the literature, extracted data, and analyzed the risk of bias in the included literature by using RevMan 5.4 software. Results A total of nine RCTs were included for analysis, including 861 children with ADHD. The results of Meta-analysis of Xiaoer Zhili Syrup combined with methylphenidate group compared to control group:hyperactivity index score[MD=-0.32, 95%CI (-0.40, -0.23), P < 0.000 01], impulsive behavior score[MD=-0.38, 95%CI (-0.48, -0.29), P < 0.000 01], learning behavior score[MD=-0.36, 95%CI (-0.43, -0.29), P < 0.000 01], adverse reaction rate[RR=0.64, 95%CI (0.46, 0.89), P=0.009], there are differences statistical significance. Conclusion Xiaoer Zhili Syrup combined with methylphenidate in the treatment of ADHD is more effective than methylphenidate alone and is safer.

R287.5

国家自然科学基金青年科学基金资助项目（82004422）